PRESSEMITTEILUNGEN

——————————————————————————–
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
——————————————————————————–

Research & Development

11.04.2011

Whitehouse Station (NJ, USA) / Vienna (Austria), April 11, 2011 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) recommended suspension of enrollment. Although the trial did not meet the pre-specified futility criteria, the DMC nonetheless recommended suspension of enrollment pending further analyses of the benefit/risk profile of the vaccine candidate. Merck and Intercell plan to provide a further update when analyses have been completed.

end of announcement euro adhoc
——————————————————————————–

Further inquiry note:

Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market

Trackback URL

Clinical Trial, Corporate Communications, Dmc, Futility, Independent Data, Intercell Ag, Interim Analysis, Investigational Vaccine, Isin, Merck, Monitoring Committee, Msd, Nyse, Risk Profile, S Aureus, Staphylococcus Aureus, Vaccine Candidate, Vienna Austria, Vse, Waibel